Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a biopharmaceutical company focused on therapies for people impacted by kidney disease, and its news flow reflects this specialization. Company announcements frequently highlight progress with Vafseo (vadadustat), a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months. Updates include prescribing access among dialysis organizations, clinical trial data such as post-hoc analyses from the INNO2VATE trials, and real-world studies like VOICE and VOCAL that examine mortality, hospitalization, and dosing strategies.
News releases also cover Akebia’s rare kidney disease pipeline, including praliciguat and AKB-097. Investors can follow milestones such as the first patient dosed in a Phase 2 trial of praliciguat for biopsy-confirmed focal segmental glomerulosclerosis (FSGS), plans to evaluate praliciguat in other rare podocytopathies, and the planned Phase 2 basket study of AKB-097 across complement-mediated rare kidney diseases, including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Additional pipeline updates may involve AKB-9090, a HIF-PH inhibitor entering Phase 1 for acute kidney injury associated with cardiac surgery.
Akebia’s news stream also includes financial results, stock option inducement grants under Nasdaq Listing Rule 5635(c)(4), licensing and supply agreements such as amendments to its Vafseo license with Medice in Europe and certain other countries, and participation in healthcare and investor conferences. For investors tracking AKBA, this news page provides a centralized view of clinical, regulatory, commercial, and corporate developments that shape the company’s kidney disease franchise and pipeline trajectory.
Akebia Therapeutics (Nasdaq: AKBA) announced dosing of the first participants in a Phase 1 randomized, double-blind, placebo-controlled SAD/MAD trial of AKB-9090, an IV HIF-PH inhibitor for cardiac surgery-associated acute kidney injury (AKI).
The study will enroll up to 70 participants, assess safety, tolerability, pharmacokinetics and pharmacodynamics, and Akebia plans to report topline data in early 2027. Akebia also noted other kidney programs: praliciguat (Phase 2) and AKB-097 (Phase 2 planned H2 2026).
Akebia Therapeutics (NASDAQ: AKBA) announced that CEO John P. Butler, CFO/Chief Business Officer Erik Ostrowski, and CMO Dr. Steven Burke will hold one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026 in New York.
No company presentations are planned; management will discuss commercial products, and data and information from Akebia’s recent R&D Day showcasing its clinical-stage kidney disease pipeline.
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to 13 newly hired employees on March 31, 2026, covering an aggregate of 679,900 shares.
The options carry a $1.39 exercise price equal to the closing price on the grant date, vest over four years (25% at one year, then quarterly), and have a 10-year term under Akebia’s inducement award program in accordance with Nasdaq Listing Rule 5635(c)(4).
Akebia (Nasdaq: AKBA) appointed Philip J. Vickers, Ph.D., to its Board of Directors effective April 1, 2026, bringing over three decades of global biopharmaceutical leadership in R&D, translational science and corporate strategy. Akebia also announced the retirement of Steven C. Gilman, Ph.D., effective April 1, 2026.
Dr. Vickers has led biotech and pharma organizations including Solu Therapeutics, Faze Medicines, Northern Biologics and served as Global Head of R&D at Shire; he co-authored ~60 peer-reviewed publications and holds numerous patents.
Akebia Therapeutics (Nasdaq: AKBA) will host a virtual R&D Day on April 2, 2026 at 10:00 AM EDT to review its clinical-stage kidney disease pipeline.
Speakers include external scientific experts and management who will discuss praliciguat (Phase 2 FSGS), AKB-097 (Phase 2 planned H2 2026) and AKB-9090 (Phase 1 planned H1 2026), plus a live Q&A and webcast access via the investor website.
Akebia Therapeutics (NASDAQ: AKBA) said its CEO John P. Butler and CFO/Chief Business Officer Erik Ostrowski will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026 at 8:00 AM ET in Miami.
A webcast will be available via the company’s Investors website following the conference. The conference runs March 8-11, 2026.
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to five newly hired employees on February 27, 2026, totaling 46,200 shares.
The options carry an exercise price of $1.31 (equal to closing price on the grant date), vest over four years (25% after one year, then quarterly), and have a 10-year term under Akebia's inducement award program.
Akebia Therapeutics (Nasdaq: AKBA) reported Q4 2025 net product revenues of $54.3M and full‑year 2025 net product revenues of $227.3M, a 49% increase versus 2024. Vafseo patient access reached 290,000; company expects significant 2026 Vafseo revenue growth. Cash totaled $184.8M, sufficient to fund operations for at least two years. Pipeline progress includes a Phase 2 praliciguat FSGS trial enrolling and a planned 2H 2026 AKB-097 Phase 2 rare kidney disease basket study.
Akebia Therapeutics (Nasdaq: AKBA) will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, before market open. A conference call to discuss results and recent business highlights will be held on Thursday, February 26, 2026 at 8:00 a.m. EST.
Investors must register to receive dial‑in details; a live webcast and an online archive will be available via the Investors section of Akebia's website.
Akebia Therapeutics (Nasdaq: AKBA) said its executive team will take part in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 9:30 AM EST.
A webcast will be available via the company’s Investors site after the conference. The summit runs February 11-12, 2026 in New York City.